is currently solvent and making every effort to stay that way.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dnaprint Genomics Inc released on Monday, 4/10/06, a 3-document, 140-page 'SB-2'
http://www.secinfo.com/d15yrh.v7q.htm
sompun's gotta happen cause I don't know how much more of your "exciting" I can take...
Think maybe Super EPO has been fast-tracked? Ummm????
"a hint!! i'm going to run the fast track......
LOL!! O.K. poker face ;)
So I gather this is the "Big News" that's already a "done deal" and the catalyst that is to propel us that you've been hinting about for some time now. If you're so sure this is the "big deal" than why is it so hard getting the timing down?
Yeah I s'pose... still 2-3 mil volume on a 300+ mil float hardly constitutes "...good volume with a spike" Hopefully we can get some real meat {like a patent issue or an actual revenue producing business deal PR} now that the SEC requirements have been met...
"Traders will be back in tomorrow, expect good volume with a spike....."
I bought another 100K block today and I didn't see any traders?
"...DNAPrint Genomics Incorporated (NASDAQ:WEDX)... Shares are up 7% to $6.23 ..
Wow! These clowns dream better than I do.
Theo
Help me out here Jeeves...??
Are you implying a direct connection here or just a representative display of typical pervasive market activities of some of the, shall we say, "less-than-honorable" hedge funds... {Are there really ANY "honorable" hedge funds} Where there is money so will there be crooks and fools.
Theo
Philosopher in his own mind... :):)
I was gonna rag on ya about the "dime by the end of the week" thingy or was it a nickel? {like it makes a difference...} But I see others are already taking you to task.:)
Monday starts a new week tho right?
Theo
Had to "play" something on my vacation day so I bought some HAL options {APRIL 72.50s} today- C'mon oil!! LOL!
Yep I see the site, but, when I bring up your link it shows the first page of 2413 pages of jobs in Turkey. I was hoping you could narrow down which page rather than have me wade through all those others looking for it. Maybe I'm just missing it on the first page??
Which page gratil1028? There's like 2000+ pages...
Theo
Thanks Bendriver-
That explains Jeeves' "NEWS THIS WEEK" ;)
I dunno Jeeves, the 'ol girl is runnin outa steam early this week like she's not even anticipatin any "NEWS". The "boyz" don't seem to be real concerned about the possibility of "NEWS" this week either looking at the diminishing daily volume...
'course we could always get another 8KA {which you could legally constitute as "NEWS" I guess}...
Theo:-/
"PREDICTION! we break .5 by weeks end......."
Fifty cents Jeeves?!? C'mon man! Even you can't seriously believe that.
langostino,
I like to read your rebuttals of Cramer as it forces me to see "both sides" as it were. However, I do have to correct you on one point and I do think it's significant. Cramer did not say anything about sugarcane or "90% of sugar cane coming from Florida and Louisiana". I tape the shows to view them at a later time {today for the episode in question} and I replayed it several times and what he said was "...90% of the sugar refining is done in Florida and Louisiana..."
Now, whether THAT statement is true or false I don't know...
Theo
I keep telling you folks- when there really is a big deal in the works, you will know. People with big bucks will be on this like flies on road apples creating HUGE volume long before ANY of you have time to even blink. The best we small investors can hope for is to be either already in when the lift off takes place, or, on the sidelines with cash if the bottom falls out. See, those with the "big bucks" seem to have the best clairvoyant capabilities. Wonder why that is?
On the flip side, we seem to have been basing a little stronger every day. I don't think that has anything to do with what transpired today. Given the amount of verbal traffic on all the trader's forums, one has to assume that momo is {again} in place. Is it warranted? If there truly is news of some sort {obviously not related to today's storyline} hanging out there, then we could see a significant run. Especially given the number of pokers DNAG has in the fire. But, again I tell you- real volume will be your best guide as to whether or not the pps movement is based on reality or speculation. JMHO
Theo SOOOooooooooooooooo Jeeves, what is/was YOUR news??
Geob,
What time Friday would you Longs Like to see the what I'm talking about? ........
Quite honestly I don't think it matters what time or day. Jeeves has been excited for many months now and we're only up approx 50% from the low {since the R/S}. I've always been a firm believer in that the market is ruthlessly efficient and will factor in any PPS propelling event {up OR down} before any regular shareholder {like us} has a chance. Best we shareholders can hope for is to have already bought in or sold out. Therefore, no offense intended, but there has been no massive volume foretelling any pending news event so I doubt that whatever piece of information you have will be much of a catalyst. Curious I am, but not holding my breath cause between Jeeves and the gang of front-runners the past few months my "get excited" senses are pretty much dulled.
Theo Holding over three times as many shares as before the R/S but still waiting on "real" financial moving news...
Hey Geob,
How 'bout some love for those of us whose cerebral cortexes aren't quite as advanced as yours by doing us a favor and dumbing it down a bit for our understanding?
Theo
NEWS: This does look promising...
http://biz.yahoo.com/iw/060314/0112989.html
Press Release Source: DNAPrint Genomics, Inc.
DNAPrint Genomics' Pharmaceuticals Division Announces That Research on Development of Super EPO Drug for Anemia Market Shows Promising Early Results
Tuesday March 14, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Mar 14, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that research to develop commercial grade PT-401, a more powerful form of the anemia drug Erythropoietin (EPO), is proceeding on schedule with the manufacturing of PT-401 in mammalian cells being shown to be very efficient. Erythropoietin (EPO) has a worldwide market exceeding $11 billion and is growing at an average annual rate of 18% for the past 5 years.
"Based on these results, research is on schedule for our first pharmaceutical product," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary. "Tests of our Super EPO dimer in animal models of anemia showed that it was several times more effective and longer acting than the currently available erythropoietin."
In vitro testing in cell cultures revealed significant positive biological activity shown by marked growth stimulation of target mammalian blood cells, either attached to solid surfaces or growing in suspension, according to Dr. Gomez. In addition, in vivo testing in mice demonstrated that even with a single injection, robust stimulation of red blood cell production was produced as assessed by an increase in the number and volume of blood cells (hematocrit). Further analytical testing showed that the dimer exhibits unique biochemical properties that distinguish it from currently marketed red blood cell growth stimulating drugs.
"We are very pleased that our original plan of achieving production efficiency with an optimal structure/activity profile has been accomplished," Dr. Gomez stated. "The next steps are to continue our scale up development work, and then select a qualified manufacturer to make drug material for our preclinical studies."
DNAPrint Genomics President and Chief Executive Officer Richard Gabriel noted that development of this novel compound is a long-term project. "These early indicators are encouraging and we will continue to pursue development and eventual commercialization of this exciting new drug compound," he said.
DNAPrint Genomics obtained an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) in February 2005 for the development of a "Super" EPO, a more potent and longer acting form of Erythropoietin (EPO). DNAPrint Pharmaceuticals' goal is to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called "Theranostics," which maximizes efficacy and minimizes side effects by tailoring and customizing medication for specific individuals and well-defined population sectors.
In June 2005, DNAPrint selected Proteos, Inc., to handle preclinical analysis of PT-401 and to manufacture the initial batches of the new drug. Please see: http://www.dnaprint.com/welcome/press/press_recent/2005/0614/
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks fourth in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
or
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint Genomics, Inc.
Alright Jeeves, I'll hold off on the condo purchase for now... :)
Sorry Jeeves, I haven't seen the post you're referring to??
Come to think of it, I haven't seen any big news either...
What gives?
Something that has puzzled for me the past couple of days is that the company had to issue an amended 8K. I have not seen where it figured significantly {O.K., I can't see where it made any difference} to the bottom line of the financials. Question is- WHY did they do it? This a "nothing" stock, "going nowhere", "no big pharma or other entity is even looking at it", and etc.,. So why was it so imperative that these filings be so clean especially when the focus was on an accounting segment {Dutchess financing} that's regulated by the SEC with the intelligence, scrutiny, and tenacity of Pee Wee Herman? Company integrity? That can't be- Frudakis and company "couldn't care less about anyone but themselves" or something akin to that- so I've read here. I don't get it. I keep asking myself who else is looking at these filings, or, why is DNAG so careful to make sure every "i" is dotted and every "t" crossed...
I'm up on this investment as well and I keep thinking of many7's tagline and how it kinda describes my position at this time:
"People who say it cannot be done should not interrupt the person doing it."
Theo
Golf4uto,
You're right we are trading higher and I think with good reason seeing the growing revenues for the Q ending September 30 alone, but, the amended 8K in question came out just tonite...
Theo
I'm not an "in depth" kinda financial wizard although I do my best to decipher the multiples and the earnings to achieve the prices of my stock interests and can usually glean and determine growth percentages, the "metrics" {same unit sales} and basic fundamental information with enough detail to keep me out of hock {except for that stupid GAP options play I blew last month but that's another story...}. Best I can determine here at this point is that there is no spin either way on this. It appears {to me} to be an omission of liability figures tied to the agreement with Dutchess Private Equities Fund, II, L.P. in regards to the Ellipsis acquisition. My impression is that the figures used in the "Qs" both for ending June 30 and September 30 should've have stated them as the amended forms do now. Caught early and rectified promptly, I see no malfeasance implied covertly or overtly. I have NOT run the numbers to confirm that statement as I stated before, it is my impression based on a quick gloss over form the original K and the amended. I'm more than happy to stand corrected if someone has the time to go over it with a fine tooth comb.
How's that for obtuse?? lol!
Theo
NEWS: http://www.secinfo.com/d15yrh.v45.htm
{Amendment to Current Report -- Dnaprint Genomics Inc · 8-K/A · For 3/1/06}
NEWS: http://biz.yahoo.com/iw/060309/0112547.html
Press Release Source: DNAPrint Genomics, Inc.
Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc.
Thursday March 9, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Mar 9, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Harvard University has received formal Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company. DNAPrint entered into an agreement with Harvard in January 2006 to sponsor continued research based on the marker, CD59, in the Harvard Medical School laboratory of Dr. Jose Halperin, a named inventor of the allowed claims. These claims, once issued, will provide Harvard additional intellectual property protection to support the development and commercialization by DNAPrint of new diagnostic tests to better define and manage diabetes more effectively.
The studies conducted by Dr. Halperin and his Harvard Medical School colleagues indicate that CD59 becomes inactivated in the presence of high blood glucose levels observed in patients with diabetes, and thus does not function normally to protect blood vessel walls from inflammatory damage. This leads to the obstruction of the many small vessels that provide critical nutrients and oxygen to organs and tissues. The common vascular disease complications suffered by individuals with diabetes -- nephropathy, retinopathy, neuropathy and atherosclerotic heart disease -- are all believed to be caused by this vascular obstruction and destruction. A test to detect CD59 in its glycated, inactive form would be a specific warning that the patient has had poor glucose control and that vascular complications are developing even before clinical symptoms show irreversible tissue and organ damage.
"Microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries are major reasons why medical costs are so high for patients with diabetes as well as causing unfortunate suffering for this group of patients of all ages," commented DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc. "Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar or glucose levels experienced by even well-controlled diabetes patients. Now we are able to move forward confidently with the development of our test, knowing that we have appropriate patent protection."
"Approval of the latest patent claims represents a milestone for Dr. Jose Halperin of Harvard Medical School and his team," commented DNA Print President and Chief Executive Officer Richard Gabriel. "According to the Center for Disease Control and Prevention, the total direct and indirect cost for both type 1 and type 2 diabetes in the United States in 2002 (four years ago) was $132 billion. Our goal is to try to help patients with diabetes understand their disease earlier, and with this knowledge, attempt to minimize their physical complications as well as reduce the associated expense to the U.S. healthcare system. We also know from physician reports that diabetes is expressed more in some patient population groups than others, so coupling our new CD59 diagnostic with our genetic ancestry information will be a valuable tool in developing and understanding the CD59 diagnostic," he concluded.
Details about the field-exclusive licensing agreement between DNAPrint Genomics, Inc. and Harvard University announced on January 26, 2006 can be found at:
http://www.dnaprint.com/welcome/press/press_recent/2006/0126/ DNAG-HARVARD.pdf
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
CEO and President
(941) 366-3400
Ron Stabiner
The Wall Street Group, Inc.
(212) 888-4848
Source: DNAPrint Genomics, Inc.
Team OT:
Thanks for the heads-up but I'm still licking my wounds over the CWTR earnings blow out today that I puked on. I had a chance to buy the April 22.50 Calls for less than half a buck in late Jan early Feb and I panned it to play the earnings of the GAP on the Old Navy turn around {earnings came out late Feb and I figured I'd score big any buy lots more CWTR cause they wouldn't report earnings til this month}. Too early for the Old Navy numbers to help and subsequently got my lower half handed to me and therefore I shied away from another retailer play. I shoulda played my instincts! Shoulda, woulda, coulda,... Cramer hates that mantra. I just need to regroup and "stay in the game"!!
Theo
dr frudaky,
"...is the euphemistically expressed "equity financing or debt" which translates into the continual issuance of shares for toxic financing to support increasing operational expenses and cause corresponding dilution of shareholder value. Absolutly nothing visible on the horizon to indicate otherwise.
JMHO from the sad fact of management's incredible inability to execute on behalf of the shareholders.
dr f
BTW, it looks like we will probably be reaching 500 million o/s well before my earlier predicted end of August date."
If we assume your opinion holds water, i.e., "nothing visible on the horizon to indicate otherwise, then do you have an explanation as to why the pps has remained above the 2 cent mark? Let's face it, if the influx of new shares is as prevalent as suggested without any catalyst "foreseen on the horizon", {and for the sake of brevity- discounting the shorting scenario that some have suggested is non-existent and has no bearing on this issue} wouldn't you expect the pps to have already been driven into the sub penny range by now?
Theo
If our share price continues to remain weak, or if any number of adverse factors or events occur, we will not have enough equity to complete future acquisitions or possibly to continue operations beyond 2005. Management is adequately confident that equity financing or debt will be available to fund our operations until revenue streams are sufficient to fund operations; however, the terms and timing of such equity or debt cannot be predicted.
Why would they be adequately confident given standard boilerplate disclaimer "we're poor and have no revenue"?? What's management got up thier sleeves?
NEWS: http://biz.yahoo.com/iw/060303/0111858.html
Press Release Source: DNAPrint Genomics, Inc.
DNAPrint Genomics Enters Into Sponsored Research Agreement With Massachusetts College of Pharmacy and Health Sciences
Friday March 3, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Mar 3, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. According to the National Institute of Mental Health, between 3 and 5 percent of children have ADHD, or approximately 2 million children in the United States.
The research will be conducted under the supervision of Dr. Mark Froimowitz, a researcher at the Boston-based College, who recently licensed the compounds to DNAPrint Genomics. The compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient's required daily dosage.
DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company's newly formed subsidiary, DNAPrint Pharmaceuticals, Inc., said his staff and Dr. Froimowitz will be working together closely to develop "theranostic" test/drug combinations based on the compounds designed to ensure that patients receive the appropriate medicine and proper dosage based on a patient's genetic constitution. Theranostic test/drug combinations are designed to reduce efficacy and side effects problems associated with conventional drug treatments.
"These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," Dr. Gomez stated. "DNAPrint's capabilities in genomics and the College's expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."
According to Dr. Froimowitz, Research Professor of Chemistry at the Massachusetts College of Pharmacy and Health Sciences, "These compounds have a number of desirable properties and possible therapeutic indications. The possibility of linking their clinical use to patient genomics represents the future of drug development."
"Many researchers believe that a strong link exists among drug addiction, ADHD and depression. There is a tremendous variation, however, across patient populations, with respect to drug response for the therapies used to treat these disorders," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc. "In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz's compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
About MCPHS
Founded in 1823, Massachusetts College of Pharmacy and Health Sciences (www.mcphs.edu) is a private coeducational college offering graduate, professional and undergraduate degrees in pharmacy and health sciences. With campuses in Boston and Worcester, Massachusetts and Manchester, New Hampshire, MCPHS is the oldest institution of higher education in the City of Boston and its pharmacy program is the second oldest in the U.S. Professional or undergraduate degrees are offered in pharmacy, nursing, physician assistant studies, dental hygiene, radiologic sciences, environmental science, health psychology, chemistry, and premedical and health studies. Graduate programs are offered in drug regulatory affairs/health policy, drug discovery and development, pharmacy systems administration, pharmaceutical sciences, medicinal chemistry, and pharmacology. The College enrolls approximately 2,800 students, who are drawn from 32 states and 30 foreign countries, and employs more than 300 faculty and staff.
MCPHS is accredited by the New England Association of Schools and Colleges and has received degree-granting authority from the Great and General Court of Massachusetts and the New Hampshire Postsecondary Education Commission.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
Company Contact:
Richard Gabriel
CEO and President
941 366-3400
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
Source: DNAPrint Genomics, Inc.
OT: What's interesting about this particular case Arch is that this one will probably be tossed out. I watched Kudlow & Company tonite and of course this case was brought up- Prevailing thought amongst 4 independent analysts was that none of them {the analysts who ran Wallstreet funds} owned OSTK nor did they have any desire to. They then proceeded to list the reasons why OTSK did not come up on their prospective radars. Compelling to say the least. Makes you wonder how that company ever got off the ground. The strange thing is, I've ordered several items {external hard drive, external DVD burner, and etc.,.} from them and have been VERY pleased. Go figure!
Theo
Crystal ball go cloudy on you Jeeves? LOL!! The "boyz" tried a different tact this time by buying sloooooowly this week- Instead of the usual bail in and bail out scenario. Still didn't do the trick though. Let's see now, there are still two more days left in February............ Crap! I hate it when a plan doesn't come together. :(
Theo
Sorry Cosmiclifeform- please see post 41772
Theo
Sorry Chris, I probably should've posted this earlier-
I voluntarily relinquished my moderator duties on this board a short time ago for various reasons so I no longer have that "power". I responded to your post to me as if I were a "regular" poster. So hopefully now this makes more sense
"Regardless of whether it "bothers" me or not, what is it you would have me personally do {That I am currently empowered to do}??"
Theo
Chris,
Regardless of whether it "bothers" me or not, what is it you would have me personally do {That I am currently empowered to do}??
Theo
"... LOL! Do you know how much DNAG paid for that publicity?
JMHO from the facts."
And just what "facts" would that be? I have to assume that if your opinion is indeed garnered from "the facts" that DNAG "paid for that publicity" then you must certainly already know how much they paid. As such I actually would like to know if this was a pimp action. TIA
Theo
many7s,
"I don't remember seeing this posted here ... "
It's there... post #41260
Doesn't hurt to remind folks tho- especially seeing that the workshop took place today...
Theo